MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

A (medicines beginning with A) B (medicines beginning with B) C (medicines beginning with C) D (medicines beginning with D) E (medicines beginning with E) F (medicines beginning with F) G (medicines beginning with G) H (medicines beginning with H) I (medicines beginning with I) K (medicines beginning with K) L (medicines beginning with L) M (medicines beginning with M) N (medicines beginning with N) O (medicines beginning with O) P (medicines beginning with P) Q (medicines beginning with Q) R (medicines beginning with R) S (medicines beginning with S) T (medicines beginning with T) U (medicines beginning with U) V (medicines beginning with V) W (medicines beginning with W) X (medicines beginning with X) Y (medicines beginning with Y) Z (medicines beginning with Z)

Medicines beginning with P

Panobinostat

Panobinostat 10mg capsules

Incompatible

Stability notes for Panobinostat 10mg capsules

Cytotoxic medicine. Not recommended due to handler risk.

Supplier

Farydak 10mg capsules (pharmaand GmbH)

Panobinostat 15mg capsules

Incompatible

Stability notes for Panobinostat 15mg capsules

Cytotoxic medicine. Not recommended due to handler risk.

Supplier

Farydak 15mg capsules (pharmaand GmbH)

Panobinostat 20mg capsules

Incompatible

Stability notes for Panobinostat 20mg capsules

Cytotoxic medicine. Not recommended due to handler risk.

Supplier

Farydak 20mg capsules (pharmaand GmbH)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.